Skip to main content
Clinical Trials/NCT02339961
NCT02339961
Withdrawn
Not Applicable

Evaluation of Lung Doppler Signals (LDS) in Detecting Pulmonary Arterial Hypertension in Patients With Systemic Sclerosis (SSc)

Echosense Ltd.0 sitesFebruary 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Systemic Sclerosis
Sponsor
Echosense Ltd.
Primary Endpoint
1. Number of SSc patients correctly identified with pulmonary hypertension severity in each of the 4 defined groups by RHC.
Status
Withdrawn
Last Updated
10 years ago

Overview

Brief Summary

Doppler signals can be recorded from the lung parenchyma by means of a pulsed Doppler ultrasound system incorporating a special signal processing package- the Transthoracic Parametric Doppler (TPD) (Echosense Ltd., Haifa, Israel). Systemic sclerosis patients often develop pulmonary vascular disease leading to pulmonary hypertension. The TPD system may provide important insight into pulmonary blood vessels characteristics by the LDS (Lung Doppler Signals) signals that are related to pulmonary hypertension. The TPD performance in detecting PAH in SSc patients will be assessed in the study.

Registry
clinicaltrials.gov
Start Date
February 2015
End Date
January 2016
Last Updated
10 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Able and willing to give signed informed consent prior to enrollment
  • Male or female, ≥ 18 years of age
  • Diagnosis of SSc according to 2013 ACR/EULAR SSc Classification Criteria (van den Hoogen 2013): Score ≥
  • Patients with RHC data available from measurement within 3 weeks prior to TPD assessment
  • No change in or initiation of PAH specific therapy between the last RHC and TPD

Exclusion Criteria

  • People unable or unwilling to give informed consent.
  • PCWP or LVEDP \> 15 mmHg
  • Any PH etiology outside Group 1 (Dana Point, 2008)
  • Pregnant women
  • Patients having severe chest wall deformity

Outcomes

Primary Outcomes

1. Number of SSc patients correctly identified with pulmonary hypertension severity in each of the 4 defined groups by RHC.

Time Frame: 12 month

Analyze Doppler data of 4 SSc groups (according to pulmonary hypertension severity) resulting in typical features. The features will be implemented in a pre-determined diagnostic algorithm that will determine the overall statistical success of the method in comparison to RHC data.

Similar Trials